Lipoprotein lipase deficiency is associated with elevated acylation stimulating protein plasma levels

Journal of Lipid Research

Volumn 50, Issue 6, 2009, Pages 1109-1119

  Paglialunga, Sabina ^a,b   Julien, Pierre ^c   Tahiri, Youssef ^a   Cadelis, Francois ^c   Bergeron, Jean ^c   Gaudet, Daniel ^d   Cianflone, Katherine ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

C3adesArg; Chylomicron; Fenofibrate; Postprandial lipemia

Indexed keywords

ACYLATION STIMULATING PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLEARANCE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENE MUTATION; GLUCOSE BLOOD LEVEL; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; HYPERLIPOPROTEINEMIA TYPE 1; MALE; NORMAL HUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 67650538311     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M800430-JLR200     Document Type: Article

References (48)

1. Murthy, V., P. Julien, and C. Gagne. 1996. Molecular pathobiology of the human lipoprotein lipase gene. Pharmacol. Ther. 70: 101-135.
2. Paglialunga, S., and K. Cianflone. 2007. Regulation of postprandial lipemia: an update on current trends. Appl. Physiol. Nutr. Metab. 32: 61-75.
3. Cianflone, K., Z. Xia, and L. Y. Chen. 2003. Critical review of Acylation Stimulating Protein physiology in humans and rodents. Biochim. Biophys. Acta. 1609: 127-143.
4. Yasruel, Z., K. Cianflone, A. D. Sniderman, M. Rosenbloom, M. Walsh, and M. A. Rodriguez. 1991. Effect of acylation stimulating protein on the triacylglycerol synthetic pathway of human adipose tissue. Lipids. 26: 495-499.
5. Kalant, D., R.Maclaren,W. Cui, R. Samanta, P. N.Monk, S. A. Laporte, and K. Cianflone. 2005. C5L2 is a functional receptor for acylation stimulating protein. J. Biol. Chem. 280: 23936-23944.
6. Kalant, D., S. A. Cain, M. Maslowska, A. D. Sniderman, K. Cianflone, and P. N. Monk. 2003. The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77/Acylation-Stimulating Protein. J. Biol. Chem. 278: 11123-11129.
7. Okinaga, S., D. Slattery, A. Humbles, Z. Zsengeller, O. Morteau, M. B. Kinrade, R. M. Brodbeck, J. E. Krause, H. R. Choe, N. P. Gerard, et al. 2003. C5L2, a nonsignaling C5A binding protein. Biochemistry. 42: 9406-9415.
8. Faraj, M., A. D. Sniderman, and K. Cianflone. 2004. ASP enhances in situ lipoprotein lipase activity by increasing fatty acid trapping in adipocytes. J. Lipid Res. 45: 657-666.
9. Farese, R. V., Jr., T. J. Yost, and R. H. Eckel. 1991. Tissue-specific regulation of lipoprotein lipase activity by insulin/glucose in normal-weight humans. Metabolism. 40: 214-216.
10. Boivin, A., I. Montplaisir, and Y. Deshaies. 1994. Postprandial modulation of lipoprotein lipase in rats with insulin resistance. Am. J. Physiol. 267: E620-E627.
11. Faraj, M., and K. Cianflone. 2004. Differential regulation of fatty acid trapping in mice adipose tissue and muscle by ASP. Am. J. Physiol. Endocrinol. Metab. 287: E150-E159.
12. Cui, W., S. Paglialunga, D. Kalant, H. Lu, C. Roy, M. Laplante, Y. Deshaies, and K. Cianflone. 2007. Acylation Stimulating Protein/C5L2 Neutralizing Antibodies alter Triglyceride Metabolism in vitro and in vivo. Am. J. Physiol. Endocrinol. Metab. 293: E1482-E1491.
13. Charlesworth, J. A., P. W. Peake, L. V. Campbell, B. A. Pussell, S. O'Grady, and T. Tzilopoulos. 1998. The influence of oral lipid loads on acylation stimulating protein (ASP) in healthy volunteers. Int. J. Obes. Relat. Metab. Disord. 22: 1096-1102.
14. Faraj, M., P. Jones, A. D. Sniderman, and K. Cianflone. 2001. Enhanced dietary fat clearance in post-obese women. J. Lipid Res. 42: 571-580.
15. Saleh, J., L. K. M. Summers, K. Cianflone, B. A. Fielding, A. D. Sniderman, and K. N. Frayn. 1998. Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period. J. Lipid Res. 39: 884-891.
16. Kalant, D., S. Phelis, B. A. Fielding, K. N. Frayn, K. Cianflone, and A. D. Sniderman. 2000. Increased postprandial fatty acid trapping in subcutaneous adipose tissue in obese women. J. Lipid Res. 41: 1963-1968.
17. Maslowska, M., T. Scantlebury, R. Germinario, and K. Cianflone. 1997. Acute in vitro production of ASP in differentiated adipocytes. J. Lipid Res. 38: 1-11.
18. Scantlebury, T., M. Maslowska, and K. Cianflone. 1998. Chylomicron specific enhancement of Acylation Stimulating Protein (ASP) and precursor protein C3 production in differentiated human adipocytes. J. Biol. Chem. 273: 20903-20909.
19. Cianflone, K., R. Zakarian, C. Couillard, B. Delplanque, J. P. Despres, and A. D. Sniderman. 2004. Fasting acylation stimulating protein is predictive of postprandial triglyceride clearance. J. Lipid Res. 45: 124-131.
20. Evans, V., and J. J. Kastelein. 2002. Lipoprotein lipase deficiency - rare or common? Cardiovasc. Drugs Ther. 16: 283-287.
21. Garenc, C., S. Aubert, J. Laroche, J. Bergeron, C. Gagne, F. Rousseau, and P. Julien. 2006. Gene polymorphisms in the Quebec population: a risk to develop hypertriglyceridemia. Biochem. Biophys. Res. Commun. 344: 588-596.
22. Cantin, B., L. D. Brun, C. Gagne, M. R. Murthy, P. J. Lupien, and P. Julien. 1992. Alterations in erythrocyte membrane lipid composition and fluidity in primary lipoprotein lipase deficiency. Biochim. Biophys. Acta. 1139: 25-31.
23. Vohl, M. C., B. Lamarche, J. Bergeron, S. Moorjani, D. Prud'homme, A. Nadeau, A. Tremblay, P. J. Lupien, C. Bouchard, and J. P. Despres. 1997. The MspI polymorphism of the apolipoprotein A-II gene as a modulator of the dyslipidemic state found in visceral obesity. Atherosclerosis. 128: 183-190.
24. Brisson, D., K. Ledoux, Y. Bosse, J. St Pierre, P. Julien, P. Perron, T. J. Hudson, M. C. Vohl, and D. Gaudet. 2002. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. Pharmacogenetics. 12: 313-320.
25. Maslowska, M., H. Vu, S. Phelis, A. D. Sniderman, B. M. Rhode, D. Blank, and K. Cianflone. 1999. Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations. Eur. J. Clin. Invest. 29: 679-686.
26. Julien, P., M. C. Vohl, D. Gaudet, C. Gagne, G. Levesque, J. P. Despres, F. Cadelis, L. D. Brun, A. Nadeau, and M. R. Ven Murthy. 1997. Hyperinsulinemia and abdominal obesity affect the expression of hypertriglyceridemia in heterozygous familial lipoprotein lipase deficiency. Diabetes. 46: 2063-2068.
27. Mero, N., L. Suurinkeroinen,M. Syvanne, P. Knudsen, H. Yki-Jarvinen, and M. R. Taskinen. 1999. Delayed clearance of postprandial large TG-rich particles in normolipidemic carriers of LPL Asn291Ser gene variant. J. Lipid Res. 40: 1663-1670.
28. Gerdes, C., R. M. Fisher, V. Nicaud, J. Boer, S. E. Humphries, P. J. Talmud, and O. Faergeman. 1997. Lipoprotein lipase variants D9N and N291S are associated with increased plasma triglyceride and lower high-density lipoprotein cholesterol concentrations: studies in the fasting and postprandial states: the European Atherosclerosis Research Studies. Circulation. 96: 733-740.
29. Pimstone, S. N., S. M. Clee, S. E. Gagne, L. Miao, H. Zhang, E. A. Stein, and M. R. Hayden. 1996. A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) results in altered postprandial chylomicron triglyceride and retinyl palmitate response in normolipidemic carriers. J. Lipid Res. 37: 1675-1684.
30. Miesenbock, G., B. Holzl, B. Foger, E. Brandstatter, B. Paulweber, F. Sandhofer, and J. R. Patsch. 1993. Heterozygous lipoprotein lipase deficiency due to a missense mutation as the cause of impaired triglyceride tolerance with multiple lipoprotein abnormalities. J. Clin. Invest. 91: 448-455.
31. Rip, J., M. C. Nierman, C. J. Ross, J. W. Jukema, M. R. Hayden, J. J. Kastelein, E. S. Stroes, and J. A. Kuivenhoven. 2006. Lipoprotein lipase S447X: a naturally occurring gain-of-functionmutation. Arterioscler. Thromb. Vasc. Biol. 26: 1236-1245.
32. Sprecher, D. L., S. L. Knauer, D. M. Black, L. A. Kaplan, A. A. Akeson, M. Dusing, D. Lattier, E. Stein, M. Rymaszewski, and D. A. Wiginton. 1991. Chylomicron-retinyl palmitate clearance in Type I hyperlipidemic families. J. Clin. Invest. 88: 985-994.
33. Cianflone, K., X. J. Zhang, J. Genest, Jr., and A. D. Sniderman. 1997. Plasma acylation stimulating protein in coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 17: 1239-1244.
34. Yang, Y., H. L. Lu, J. Zhang, H. Y. Yu, H. W. Wang, M. X. Zhang, and K. Cianflone. 2006. Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs obese type 2 diabetes. Int. J. Obes. (Lond). 30: 439-446.
35. Yu, H., Y. Yang, M. Zhang, H. Lu, J. Zhang, H.Wang, and K. Cianflone. 2006. Thyroid status influence on adiponectin, acylation stimulating protein (ASP) and complement C3 in hyperthyroid and hypothyroid subjects. Nutr. Metab. (Lond). 3: 13-21.
36. Wu, Y., J. Zhang, Y. Wen, H. Wang, M. Zhang, and K. Cianflone. 2009. Increased acylation-stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome. Fertil. Steril. 91: 213-219.
37. Brun, L. D., C. Gagne, P. Julien, A. Tremblay, S. Moorjani, C. Bouchard, and P. J. Lipien. 1989. Familial lipoprotein lipase activity deficiency: study of total body fatness and subcutaneous fat tissue distribution. Metabolism. 38: 1005-1009.
38. Peeva, E., L. D. Brun, M. R. Ven Murthy, J. P. Despres, T. Normand, C. Gagne, P. J. Lupien, and P. Julien. 1992. Adipose cell size and distribution in familial lipoprotein lipase deficiency. Int. J. Obes. Relat. Metab. Disord. 16: 737-744.
39. Tamasawa, N., J. Matsui, H. Murakami, J. Tanabe, K. Matsuki, Y. Ogawa, Y. Ikeda, A. Takagi, and T. Suda. 2006. Glucose-stimulated insulin response in non-diabetic patients with lipoprotein lipase deficiency and hypertriglyceridemia. Diabetes Res. Clin. Pract. 72: 6-11.
40. Fujita, T., T. Fujioka, T. Murakami, A. Satomura, Y. Fuke, and K. Matsumoto. 2007. Chylomicron accelerates C3 tick-over by regulating the role of factor H, leading to overproduction of acylation stimulating protein. J. Clin. Lab. Anal. 21: 14-23.
41. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 2001. JAMA. 285: 2486-2497.
42. Duval, C., M. Muller, and S. Kersten. 2007. PPARalpha and dyslipidemia. Biochim. Biophys. Acta. 1771: 961-971.
43. Kaser, S., A. Sandhofer, B. Holzl, R. Gander, C. F. Ebenbichler, B. Paulweber, and J. R. Patsch. 2003. Phospholipid and cholesteryl ester transfer are increased in lipoprotein lipase deficiency. J. Intern. Med. 253: 208-216.
44. Braissant, O., F. Foufelle, C. Scotto, M. Dauca, and W. Wahli. 1996. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 137: 354-366.
45. Cabrero, A., M. Alegret, R. M. Sanchez, T. Adzet, J. C. Laguna, and M. Vazquez. 2001. Bezafibrate reduces mRNA levels of adipocyte markers and increases fatty acid oxidation in primary culture of adipocytes. Diabetes. 50: 1883-1890.
46. Zhao, S. P., and J. Wu. 2004. Fenofibrate reduces tumor necrosis factor-alpha serum concentration and adipocyte secretion of hypercholesterolemic rabbits. Clin. Chim. Acta. 347: 145-150.
47. Hiuge, A., A. Tenenbaum, N. Maeda, M. Benderly, M. Kumada, E. Z. Fisman, D. Tanne, Z. Matas, T. Hibuse, K. Fujita, et al. 2007. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler. Thromb. Vasc. Biol. 27: 635-641.
48. Choi, K. C., O. H. Ryu, K.W. Lee, H. Y. Kim, J. A. Seo, S. G. Kim, N. H. Kim, D. S. Choi, S. H. Baik, and K. M. Choi. 2005. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem. Biophys. Res. Commun. 336: 747-753.